论文部分内容阅读
目的:探讨紫杉醇联合顺铂方案对局部晚期宫颈癌患者MACC1及Ezrin蛋白表达的影响。方法:选取2013年8月至2015年8月收入本院的68例局部晚期宫颈癌患者为研究对象,采用随机数字表法分为观察组和对照组,各34例。对照组接受顺铂联合5-氟尿嘧啶辅助化疗,观察组采用紫杉醇联合顺铂辅助化疗。持续治疗6周后,分析比较两组患者的临床治疗效果、MACC1和Ezrin蛋白表达情况。结果:观察组的客观缓解率显著高于对照组(χ~2=10.16,P<0.05),观察组的MACC1和Ezrin蛋白表达显著低于对照组(P<0.05),不良反应发生率(11.8%)与对照组(17.6%)差异无统计学意义(χ~2=0.40,P>0.05)。结论:紫杉醇联合顺铂用于局部晚期宫颈癌辅助化疗效果显著,能够有效降低宫颈癌组织中的MACC1与Ezrin蛋白的表达,有利于患者康复,值得临床推广。
Objective: To investigate the effect of paclitaxel plus cisplatin on the expression of MACC1 and Ezrin in patients with locally advanced cervical cancer. Methods: Sixty-eight patients with locally advanced cervical cancer who were admitted to our hospital from August 2013 to August 2015 were selected as study subjects and divided into observation group and control group by random number table. Control group received cisplatin combined with 5 - fluorouracil adjuvant chemotherapy, the observation group with paclitaxel plus cisplatin adjuvant chemotherapy. After 6 weeks of continuous treatment, the clinical effects, MACC1 and Ezrin protein expression in two groups were analyzed and compared. Results: The objective remission rate in observation group was significantly higher than that in control group (χ ~ 2 = 10.16, P <0.05). The expression of MACC1 and Ezrin in observation group was significantly lower than that in control group (P <0.05) %) And control group (17.6%) showed no significant difference (χ ~ 2 = 0.40, P> 0.05). Conclusions: Paclitaxel combined with cisplatin is effective in adjuvant chemotherapy for locally advanced cervical cancer, which can effectively reduce the expression of MACC1 and Ezrin protein in cervical cancer and is beneficial to patients’ recovery. It is worthy of clinical promotion.